Literature DB >> 11459780

Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells.

T Kogai1, J M Hershman, K Motomura, T Endo, T Onaya, G A Brent.   

Abstract

The absence of TSH-stimulated radioiodide uptake in differentiated thyroid cancer is associated with a high recurrence rate and reduced survival. We studied regulation of the sodium/iodide symporter gene in human papillary thyroid cancer cell lines (BHP) and primary human thyroid cells. BHP cells expressed very low levels of sodium/iodide symporter mRNA and did not concentrate iodide, but iodide uptake was restored to levels seen in FRTL-5 rat thyroid cells by stable transfection of a sodium/iodide symporter cDNA. Sodium/iodide symporter gene expression, therefore, was necessary and sufficient for iodide uptake in BHP cells. We cloned the human sodium/iodide symporter gene 5'-flanking region and analyzed progressive 5'-deletions in transient transfections. We identified a region, -596 to -268, essential to confer full promoter activity in primary normal human thyroid cells. Sodium/iodide symporter promoter activity in four BHP cell lines, however, was markedly reduced, consistent with down-regulation of the endogenous sodium/iodide symporter gene. Nuclear extracts from BHP 2-7 cells had reduced or absent binding to regions of the sodium/iodide symporter promoter shown to be critical for expression, compared with nuclear extracts from FRTL-5 cells. Competition studies indicated that these nuclear proteins were not known thyroid transcription factors. Modifications of the sodium/iodide symporter promoter with demethylation or histone acetylation did not increase sodium/iodide symporter expression, and no deletions of the critical regulatory region were identified in the endogenous gene in BHP cells. Regulation of the sodium/iodide symporter 5'-flanking region in transient transfection paralleled endogenous sodium/iodide symporter expression. Reduced expression of potential novel nuclear factor(s) in these cell lines may contribute to reduced sodium/iodide symporter expression resulting in absence of iodide uptake in some papillary thyroid cancers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11459780     DOI: 10.1210/endo.142.8.8344

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy.

Authors:  W Xia; D Li; G Wang; J Ni; J Zhuang; M Ha; J Wang; Y Ye
Journal:  Cancer Gene Ther       Date:  2016-09-09       Impact factor: 5.987

Review 2.  Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.

Authors:  Stefania Bulotta; Marilena Celano; Giuseppe Costante; Diego Russo
Journal:  Endocrine       Date:  2015-12-21       Impact factor: 3.633

Review 3.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

4.  Identification of cyclic adenosine 3',5'-monophosphate response element modulator as an activator of the human sodium/iodide symporter upstream enhancer.

Authors:  Mike S Fenton; Kenneth M Marion; Jerome M Hershman
Journal:  Endocrinology       Date:  2008-01-17       Impact factor: 4.736

5.  Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers.

Authors:  David Tai; Donald Poon
Journal:  J Oncol       Date:  2010-08-24       Impact factor: 4.375

6.  Retinoic acid stimulation of the sodium/iodide symporter in MCF-7 breast cancer cells is mediated by the insulin growth factor-I/phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase signaling pathways.

Authors:  Takahiko Kogai; Emi Ohashi; Megan S Jacobs; Saima Sajid-Crockett; Myrna L Fisher; Yoko Kanamoto; Gregory A Brent
Journal:  J Clin Endocrinol Metab       Date:  2008-03-04       Impact factor: 5.958

7.  Dual-source dual-energy computed tomography-derived quantitative parameters combined with machine learning for the differential diagnosis of benign and malignant thyroid nodules.

Authors:  Liling Jiang; Daihong Liu; Ling Long; Jiao Chen; Xiaosong Lan; Jiuquan Zhang
Journal:  Quant Imaging Med Surg       Date:  2022-02

8.  Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation?

Authors:  Eusebio Chiefari; Antonio Brunetti; Franco Arturi; Jean-Michel Bidart; Diego Russo; Martin Schlumberger; Sebastiano Filetti
Journal:  BMC Cancer       Date:  2002-12-10       Impact factor: 4.430

9.  Identification of benign and malignant thyroid nodules by in vivo iodine concentration measurement using single-source dual energy CT: A retrospective diagnostic accuracy study.

Authors:  Shun-Yu Gao; Xiao-Yan Zhang; Wei Wei; Xiao-Ting Li; Yan-Ling Li; Min Xu; Ying-Shi Sun; Xiao-Peng Zhang
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.